Can These Plants Fight Breast Cancer? New Research on Natural Cytotoxicity
"Exploring the potential of Nigerian medicinal plants to modulate key genes in breast cancer cells: A promising step towards natural cancer therapies."
Breast cancer remains a leading cause of cancer deaths among women worldwide, underscoring the urgent need for effective treatments. While conventional therapies have advanced, the exploration of natural compounds as potential anticancer agents is gaining momentum. Many plants used in traditional medicine are believed to possess anticancer properties, but rigorous scientific evaluation is crucial to validate these claims.
A recent study has focused on six plants native to Nigeria, examining their cytotoxic effects and their influence on key genes involved in cancer development. Specifically, researchers investigated how extracts from these plants affect the expression of the TP53 and retinoblastoma (Rb) genes in breast cancer cells. These genes play critical roles in suppressing tumor growth, and understanding how natural compounds can modulate their activity could pave the way for novel cancer therapies.
This article delves into the findings of this research, explaining how the plant extracts were prepared, how their cytotoxicity was assessed, and what effects they had on gene expression in breast cancer cell lines. By exploring the modulatory potentials of these plant extracts, we gain insights into potential new avenues for breast cancer treatment and prevention.
Breast Cancer’s Global Impact and Treatment Choices
Breast cancer is the most common cancer and the leading cause of cancer-related deaths among women worldwide, according to a review of herbal medicine in breast cancer therapy. Conventional treatments—including surgery, chemotherapy, radiotherapy, hormone therapy, and targeted therapies—have improved outcomes, but drug resistance, recurrence, and adverse effects remain challenges. A Yale-reported analysis using the National Cancer Database, which captures around 70% of newly diagnosed cancer patients in the United States, examined more than 2 million patients with breast cancer and linked alternative medicine alone to worse outcomes. Natural products are being studied as potential complements, but clinical implementation remains challenging.
Established Treatments and the Move Toward Personalization
Surgery, chemotherapy, and radiation therapy have long been standard breast cancer treatments, while treatment choices can also include hormone and targeted therapies. A 2025 review describes precision medicine as a shift from uniform approaches toward strategies tailored to the characteristics of each patient and tumor, with the aim of improving efficacy, reducing adverse effects, and supporting quality of life. Natural products and their derivatives are being investigated for anticancer potential, with future strategies focused on enhancing their activity, targeting, and bioavailability while minimizing side effects. Complementary approaches such as acupuncture, detoxification diets, traditional Chinese medicine, and antioxidants are also used, but should not replace anticancer drugs with special diets.
Unlocking the Anticancer Potential of Nigerian Plants
The study, published in the Journal of Pharmacognosy and Phytotherapy, selected six Nigerian plants known in traditional medicine for their purported anticancer properties: Tapinanthes bangwensis (Tba), Spilanthes filicaulis (Sfi), Anthocleista djalonensis (Adj), Curculigo pilosa (Cpi), Icacina trichantha (Itr), and Gladiolus psittacinus (Gps). Researchers prepared various extracts from these plants, including crude extracts and fractions obtained using different solvents like hexane, chloroform, and ethylacetate.
- Sfi-HF: Hexane fraction of Spilanthes filicaulis. Showed the highest cytotoxic effect on brine shrimps, with a low signal of p53 gene expression but a high intensity of Rb gene expression in MCF-7 cell lines.
- Gps-CE: Crude extract of Gladiolus psittacinus. Demonstrated a significant increase in TP53 gene expression and a high intensity of Rb gene expression.
Plant Studies and Cell-Growth Pathways
The supplied study snippets discuss p53, a tumor suppressor that can eliminate abnormal cells and inhibit their multiplication by inducing apoptosis. One study addresses antiproliferative effects of selected medicinal plants on cancerous and normal cells, while another examines gene-expression-mediated antiproliferative potential and safety. A separate investigation of Schinziophyton rautanenii and Colophospermum mopane reports that RB-gene mutations have been found in about 15% of breast cancer cases and can disrupt the RB pathway when the gene is over-expressed. These excerpts describe research questions and biological context; they do not establish that the plants treat breast cancer in people.
Evidence Gaps and Persistent Treatment Challenges
The supplied evaluation of selected cytotoxic plants notes that relatively few have undergone acceptable scientific evaluation for potential anticancer effects. A 2026 review reports that breast cancer treatment still faces challenges related to aggressive disease and a lack of targeted therapies, while traditional treatments have improved survival but can involve drug resistance and adverse effects. Natural and complementary therapies may support a person’s mind and body during treatment, as described by Medical News Today. The available excerpts therefore point to both evidence gaps for plant-based anticancer claims and continuing limitations in conventional care.
Implications and Future Directions
This study provides valuable insights into the potential of Nigerian medicinal plants to combat breast cancer by modulating key genes involved in tumor suppression. The findings suggest that Sfi-HF and Gps-CE, in particular, warrant further investigation as potential sources of anticancer compounds.
Promising Complementary Research, Uneven Evidence
A 2026 evidence map describes itself as the first comprehensive visual overview of systematic reviews on herbal medicine for breast cancer. It finds that the reviews cluster around treatment-related symptom management, while their methodological quality is consistently low. A 2025 narrative review says breast cancer treatment decisions are guided by disease stage, histological grade, molecular receptor status, and genetic mutations. Another review highlights herbal medicines’ multi-targeted actions and potential as complementary approaches, but these reported possibilities do not establish clinical effectiveness.
Researching Phytochemicals Amid Treatment Tradeoffs
A 2025 review identifies phytochemicals as an area of therapeutic-potential research for breast cancer. It notes that existing strategies—including surgery, chemotherapy, radiotherapy, and hormonal therapy—offer substantial clinical benefits, but may be associated with high costs, toxicity, drug resistance, metastasis, and tumor-related challenges. The source frames phytochemicals as a research direction; the supplied excerpt does not establish that they are effective treatments for patients.
The Challenge of Clinical Translation
Natural products are an emerging area of breast cancer therapy research, with the source describing possible benefits such as increasing treatment effectiveness, reducing treatment side effects, and improving quality of life. It also emphasizes that moving this evidence into clinical use remains challenging. These reported potential benefits should therefore be understood alongside the unresolved implementation challenge.
Integrative Care and Patient Outcomes
Complementary and alternative medicine approaches are widely used by people with breast cancer, and a 2024 report presents a case series of four patients who received a pragmatic integrative medicine protocol in an inpatient integrative oncology setting. A 2026 cohort study examines the association between complementary and alternative medicine used alongside traditional therapies—including surgery, chemotherapy, radiation, endocrine therapy, and immunotherapy—and survival. Another supplied source notes that a study lacked relevant information on pathological and clinical staging, while a separate cohort study indicated improved quality of life with integrative traditional Chinese and Western medicine treatment. These excerpts describe varied study designs and outcomes, rather than establishing a single overall effect.
However, it's important to note that this research was conducted in vitro, using breast cancer cell lines. Further studies are needed to confirm these findings in vivo, using animal models and ultimately, human clinical trials. Identifying the specific bioactive compounds responsible for the observed effects and understanding their mechanisms of action are also critical steps in developing effective cancer therapies.
As natural medicine and plant-based remedies gain traction, studies like this highlight the importance of rigorous scientific investigation. By bridging traditional knowledge with modern research, we can unlock the potential of natural compounds to address pressing health challenges like breast cancer.